MBRX实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses...

Stats
今日成交量	16 435.00
平均成交量	107 577
市值	11.18M
EPS	$0 ( 2024-03-27 )
下一个收益日期	( $-3.59 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.330
ATR14	$0.0790 (1.57%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-26	Foster Jonathan P.	Buy	28 986	Common Stock
2023-12-26	George Robert E.	Buy	14 493	Common Stock
2023-12-26	Klemp Walter V	Buy	188 404	Common Stock
2023-07-11	Klemp Walter V	Sell	13 204	Restricted Stock Units
2023-07-11	Klemp Walter V	Buy	13 204	Common Stock

INSIDER POWER
82.97
Last 98 transactions
Buy: 6 351 373 \| Sell: 471 392

Moleculin Biotech Inc 相关性

10 最正相关
TXG	0.897
NEOG	0.894
BIRD	0.89
NDRA	0.886
ADPT	0.879
RVNC	0.878
GIII	0.874
GOCO	0.868
DCFC	0.865
NDLS	0.859

10 最负相关
QQD	-0.87
QQC	-0.867
PRTC	-0.857
BCOR	-0.834
RAIN	-0.823
MSSA	-0.82
HZNP	-0.819
LCYAU	-0.819
MSAC	-0.817
GHRS	-0.817

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Moleculin Biotech Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-127 000 (0.00 %)
EPS:	$-15.07

FY	2023
营收:	$0
毛利润:	$-127 000 (0.00 %)
EPS:	$-15.07

FY	2022
营收:	$0
毛利润:	$-222 000 (0.00 %)
EPS:	$-14.37

FY	2021
营收:	$0.00
毛利润:	$-164 000 (0.00 %)
EPS:	$-1.614

Financial Reports:

No articles found.

Moleculin Biotech Inc

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.

实时更新： Moleculin Biotech Inc [MBRX]

Upcoming Earnings Alert